| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Gilles Chatellier | |
| Holger Thiele | |||
| Gerhard Schuler | |||
| Antoine Lafont | |||
| Bachir Allam | |||
| P2860 | cites work | LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study | Q44519101 |
| Cardiogenic shock complicating acute myocardial infarction: predictors of death. GUSTO Investigators. Global Utilization of Streptokinase and Tissue-Plasminogen Activator for Occluded Coronary Arteries | Q44617277 | ||
| Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee | Q45002081 | ||
| Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes | Q45092053 | ||
| Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. | Q45173221 | ||
| Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point | Q46750174 | ||
| Intra-aortic balloon counterpulsation in patients with acute myocardial infarction complicated by cardiogenic shock: the prospective, randomized IABP SHOCK Trial for attenuation of multiorgan dysfunction syndrome | Q48453351 | ||
| Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. | Q51535796 | ||
| Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); Results of the primary PCI registry of the Arbeitsgemeinschaft Leit | Q51708697 | ||
| Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries f | Q52925624 | ||
| Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction | Q56944585 | ||
| Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation | Q56944855 | ||
| Contemporary reperfusion therapy for cardiogenic shock: The GUSTO-I trial experience | Q56945507 | ||
| ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary | Q56986933 | ||
| Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry | Q58371222 | ||
| One-Year Survival Following Early Revascularization for Cardiogenic Shock | Q58975860 | ||
| Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: | Q22242896 | ||
| Comparison of Dopamine and Norepinephrine in the Treatment of Shock | Q22250880 | ||
| Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction | Q24683044 | ||
| A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS) | Q28193446 | ||
| Bivalirudin during primary PCI in acute myocardial infarction | Q28281179 | ||
| The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. | Q30652858 | ||
| Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. | Q33872047 | ||
| Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (S | Q34454112 | ||
| Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock | Q34495039 | ||
| The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis | Q34776831 | ||
| A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction | Q34879663 | ||
| Percutaneous left ventricular assist devices vs. intra-aortic balloon pump counterpulsation for treatment of cardiogenic shock: a meta-analysis of controlled trials | Q34992995 | ||
| Evidence-based use of levosimendan in different clinical settings | Q36472079 | ||
| Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes | Q36800606 | ||
| Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock | Q36857219 | ||
| Cardiogenic shock: current concepts and improving outcomes | Q37077213 | ||
| Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective | Q37315638 | ||
| A systematic review and meta-analysis of intra-aortic balloon pump therapy in ST-elevation myocardial infarction: should we change the guidelines? | Q37377110 | ||
| Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials | Q37624213 | ||
| Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial | Q38398337 | ||
| Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries | Q38504060 | ||
| A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. | Q39511178 | ||
| Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial | Q44075258 | ||
| P433 | issue | 15 | |
| P921 | main subject | myocardial infarction | Q12152 |
| acute myocardial infarction | Q18558122 | ||
| P304 | page(s) | 1828-1835 | |
| P577 | publication date | 2010-07-07 | |
| P1433 | published in | European Heart Journal | Q2286839 |
| P1476 | title | Shock in acute myocardial infarction: the Cape Horn for trials? | |
| P478 | volume | 31 |
| Q37953885 | 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi |
| Q40963704 | An inspection of therapeutic hypothermia preceding coronary reperfusion in patients with a cardiogenic shock complicating anterior ST-segment elevation myocardial infarction |
| Q35205258 | Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes |
| Q49835894 | Cardiogenic shock : Current evidence |
| Q37974559 | Cardiogenic shock in ACS. Part 2: Role of mechanical circulatory support |
| Q35993544 | Cellular responses to mild heat stress |
| Q47603457 | Clinical application of intra-aortic balloon counterpulsation in high-risk patients undergoing cardiac surgery |
| Q26751457 | Continuous internal counterpulsation as a bridge to recovery in acute and chronic heart failure |
| Q42645345 | Efficacy of prophylactic intra-aortic balloon pump therapy in chronic heart failure patients undergoing cardiac surgery |
| Q50027199 | Extracorporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): the need for a better definition of refractory cardiogenic shock |
| Q39423441 | Fifteen-year trends in the management of cardiogenic shock and associated 1-year mortality in elderly patients with acute myocardial infarction: the FAST-MI programme |
| Q41671876 | First-in-man analysis of the i-cor assist device in patients with cardiogenic shock |
| Q38284058 | Important role of mechanical circulatory support in acute myocardial infarction complicated by cardiogenic shock |
| Q58158747 | Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French Nationwide Registries |
| Q47820170 | Incidence, treatment strategies and outcomes of acute coronary syndrome with and without ongoing myocardial ischaemia: results from the CZECH-3 registry |
| Q40964440 | Influence of cardiogenic shock with or without the use of intra-aortic balloon pump on mortality in patients with ST-segment elevation myocardial infarction |
| Q39026592 | Interventional therapies in acute myocardial infarction complicated by cardiogenic shock |
| Q38174977 | Intra-aortic balloon counterpulsation - basic principles and clinical evidence |
| Q42617042 | Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II): final 12 month results of a randomised, open-label trial |
| Q39884504 | Intra-aortic balloon pump combined with mechanical ventilation for treating patients aged > 60 years in cardiogenic shock: Retrospective analysis |
| Q38794418 | Intra-aortic balloon pump in cardiogenic shock: state of the art. |
| Q36151537 | Intra-aortic balloon pump may grant no benefit to improve the mortality of patients with acute myocardial infarction in short and long term: an updated meta-analysis |
| Q35568347 | Intraaortic balloon counterpulsation and microcirculation in cardiogenic shock complicating myocardial infarction: an IABP-SHOCK II substudy |
| Q37208712 | Is there light at the end of the tunnel?-new perspectives in ECMO survival. |
| Q40643242 | Limb salvage following iatrogenic arterial injury: complications of cardiac support using intra-aortic balloon pumps. |
| Q40745961 | Long-Term Intra-Aortic Balloon Pump Support as Bridge to Left Ventricular Assist Device Implantation |
| Q38366956 | Management of cardiogenic shock |
| Q64248971 | Mechanical circulatory support for refractory cardiogenic shock post-acute myocardial infarction-a decade of lessons |
| Q34312460 | Mechanical circulatory support in acute cardiogenic shock |
| Q37786652 | Microcirculation in cardiogenic shock: from scientific bystander to therapy target |
| Q46125420 | Novel prediction tool for veno-arterial extracorporeal membranous oxygenation in acute myocardial infarction patients. |
| Q37619076 | Optimal Timing of Percutaneous Coronary Intervention for Nonculprit Vessel in Patients with ST-Segment Elevation Myocardial Infarction and Multivessel Disease |
| Q64889938 | Optimal timing of staged percutaneous coronary intervention in ST-segment elevation myocardial infarction patients with multivessel disease. |
| Q36233577 | Outcomes in patients undergoing percutaneous ventricular assist device implantation for cardiogenic shock |
| Q38519847 | Percutaneous Mechanical Support in Cardiogenic Shock: A Review |
| Q36133181 | Phagocytosis of apoptotic cells: a matter of balance |
| Q50767945 | Predictors of mortality in patients with cardiogenic shock treated with primary percutaneous coronary intervention and intra-aortic balloon counterpulsation. |
| Q61650913 | Primary Angioplasty For Patients in Cardiogenic Shock: Optimal Management |
| Q33749968 | Prognostic value of admission blood glucose level in patients with and without diabetes mellitus who sustain ST segment elevation myocardial infarction complicated by cardiogenic shock |
| Q47109645 | Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial |
| Q38496703 | Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Em |
| Q90149292 | Red Blood Cell Distribution Width Is Associated with All-Cause Mortality in Critically Ill Patients with Cardiogenic Shock |
| Q38198409 | Reprint of "Intra-aortic balloon counterpulsation--basic principles and clinical evidence". |
| Q35871025 | Risk factors and clinical characteristics of in-hospital death in acute myocardial infarction with IABP support. |
| Q40405268 | Shenfu Injection () inhibits inflammation in patients with acute myocardial infarction complicated by cardiac shock |
| Q40031577 | Statins for patients with cardiogenic shock |
| Q40574180 | Temporal trends in the epidemiology, management, and outcome of patients with cardiogenic shock complicating acute coronary syndromes |
| Q36710155 | The outcomes of intra-aortic balloon pump usage in patients with acute myocardial infarction: a comprehensive meta-analysis of 33 clinical trials and 18,889 patients |
| Q42369297 | Veno-arterial extracorporeal membrane oxygenation (VA ECMO) in postcardiotomy cardiogenic shock: how much pump flow is enough? |
| Q42332758 | What is extracorporeal cardiopulmonary resuscitation? |
| Q38008529 | What is the evidence for IABP in STEMI with and without cardiogenic shock? |
| Q86863915 | [Mechanical support in cardiogenic shock] |
| Q88107083 | [PCI strategies in patients with acute myocardial infarction and cardiogenic shock : CULPRIT-SHOCK] |
Search more.